Ultragenyx wins FDA approval for FAYUVI in Sanfilippo syndrome Type A
Ultragenyx Pharmaceutical has secured standard full FDA approval for FAYUVI (rebisufligene etisparvovec-hopf), a single-dose intravenous AAV9 gene therapy for paediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), commonly known as Sanfilippo syndrome Type A. The approval, granted on 17 September 2026, marks the first-ever authorised treatment for the condition and Ultragenyx's second gene therapy approval overall.
Sanfilippo syndrome Type A is an ultra-rare lysosomal storage disease driven by a deficiency in the sulfamidase (SGSH) enzyme. The resulting accumulation of heparan sulfate causes rapid, progressive neurodegeneration from early childhood, with a median life expectancy of just 15 years. The condition is estimated to affect between 3,000 and 5,000 patients in commercially accessible geographies worldwide.
Clinical evidence
Approval rests on data from the pivotal Transpher A trial and its long-term follow-up studies, with observations now extending to nearly eight years. In the modified intention-to-treat population (n=17), FAYUVI-treated patients demonstrated a 23.5-point higher Bayley-III Cognitive raw score compared with an external natural history cohort (n=27) over the 24-to-60-month assessment window (p<0.0001). Reductions in cerebrospinal fluid heparan sulfate levels were sustained across all age groups, providing biochemical corroboration of enzyme replacement activity.
The safety profile includes hepatotoxicity as a key monitored risk: elevated liver enzymes were reported in 85% of patients, and a mandatory corticosteroid regimen before and after infusion is required. Thrombocytopenia was also observed, and the label carries a warning regarding the theoretical risk of malignancy associated with AAV vector DNA integration, consistent with class-wide labelling requirements for gene therapies.
Kevin M. Flanigan, director of the Center for Gene Therapy at Nationwide Children's Hospital and principal investigator on the pivotal study, noted that the underlying vector was first developed at that institution more than a decade ago, making the approval "additionally gratifying" for the research team.
Access and market context
Ultragenyx expects commercial supply to reach its network of Qualified Treatment Centers within 30 to 60 days of approval. The product is manufactured entirely in the United States, at Ultragenyx's own facility in Bedford, Massachusetts, and at contract manufacturer Andelyn Biosciences in Columbus, Ohio. The company's UltraCare programme will provide dedicated gene therapy guides to assist families with insurance navigation and treatment logistics.
The development history is notable. The therapy was originally developed at Ohio State University and Nationwide Children's Hospital, licensed to Abeona Therapeutics, and subsequently out-licensed to Ultragenyx when funding constraints arose despite positive clinical data. The circuitous path underscores a recurring challenge in ultra-rare gene therapy: the cost and commercial uncertainty of serving tiny patient populations can stall programmes even when science is supportive.
Ultragenyx also received a Priority Review Voucher upon approval, a transferable regulatory asset that has historically traded at values between $100 million and $200 million, representing a meaningful near-term financial consideration alongside the commercial launch.
The broader rare-disease gene therapy market is at an inflection point. Several AAV-based programmes targeting ultra-rare neurodegenerative conditions are in late-stage development, and regulators on both sides of the Atlantic have been refining accelerated pathways for conditions with no existing treatment options. FAYUVI's standard full approval, rather than accelerated approval, is a meaningful regulatory signal: the Bayley-III cognitive endpoint, anchored against a natural history comparator, satisfied the FDA's threshold for full authorisation in a disease where randomised controlled trials are impractical given patient numbers. That precedent may inform the regulatory strategy for other developers targeting comparably small populations.